» Articles » PMID: 15246162

Human Placenta-derived Mesenchymal Progenitor Cells Support Culture Expansion of Long-term Culture-initiating Cells from Cord Blood CD34+ Cells

Overview
Journal Exp Hematol
Specialty Hematology
Date 2004 Jul 13
PMID 15246162
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Allogeneic transplantation with umbilical cord blood (UCB) in adult recipients is limited mainly by a low CD34+ cell dose. To overcome this shortcoming, human placenta as a novel source of human mesenchymal progenitor cell (MPC) was incorporated in an attempt to expand CD34+ cells from UCB in vitro.

Materials And Methods: Human placenta MPC was isolated and characterized by morphologic, immunophenotypical, and functional analysis. UCB CD34+ cells were expanded by coculture with placental MPC. Suitable aliquots of cells were used to monitor cell production, clonogenic activity, and long-term culture-initiating culture (LTC-IC) output. Finally, the immunoregulatory effect of placental MPC was evaluated by T-cell proliferation assay.

Results: In its undifferentiated state, placental MPC displayed fibroblastoid morphology; was CD73, CD105, CD29, CD44, HLA-ABC, and CD166 positive; produced fibronectin, laminin, and vimentin; but was negative for CD14, CD31, CD34, CD45, HLA-DR, and alpha-smooth muscle actin. Functionally, it could be induced into adipocytes, osteocytes, and chondrocytes. In vitro expansion of UCB hematopoietic cells, when cocultured with placental MPC in the presence of cytokines, was significantly enhanced: CD34+ cells by 14.89 +/- 2.32 fold; colony-forming cell (CFC) by 36.73 +/- 5.79 fold; and LTC-IC by 7.43 +/- 2.66 fold. Moreover, placental MPC could suppress T-cell proliferation induced by cellular stimuli.

Conclusion: These results strongly suggest that human placental MPC may be a suitable feeder layer for expansion of hematopoietic progenitors from UCB in vitro.

Citing Articles

hUC-MSCs Attenuate Acute Graft-Versus-Host Disease through Chi3l1 Repression of Th17 Differentiation.

Liu W, Yuan F, Bai H, Liu Y, Li X, Wang Y Stem Cells Int. 2022; 2022:1052166.

PMID: 36277038 PMC: 9582900. DOI: 10.1155/2022/1052166.


The Effect of Amniotic Tissue on Spinal Interventions: A Systematic Review.

Moore M, Deckey D, Pollock J, Smith J, Tokish J, Neal M Int J Spine Surg. 2022; 17(1):32-42.

PMID: 36253081 PMC: 10025852. DOI: 10.14444/8380.


Functionalized 3D scaffolds for engineering the hematopoietic niche.

Bruschi M, Vanzolini T, Sahu N, Balduini A, Magnani M, Fraternale A Front Bioeng Biotechnol. 2022; 10:968086.

PMID: 36061428 PMC: 9428512. DOI: 10.3389/fbioe.2022.968086.


Isolation and characterization of mesenchymal stem cells in orthopaedics and the emergence of compact bone mesenchymal stem cells as a promising surgical adjunct.

Anastasio A, Gergues M, Lebhar M, Rameshwar P, Fernandez-Moure J World J Stem Cells. 2020; 12(11):1341-1353.

PMID: 33312402 PMC: 7705465. DOI: 10.4252/wjsc.v12.i11.1341.


COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy.

Verma Y, Verma R, Tyagi N, Behl A, Kumar S, Gangenahalli G Stem Cell Rev Rep. 2020; 17(1):113-131.

PMID: 32920752 PMC: 7486977. DOI: 10.1007/s12015-020-10037-2.